Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Do worse scores on patient-reported outcomes predict the progression of interstitial lung disease (ILD)?

Marlies S. Wijsenbeek, Paolo Spagnolo, Martin Kolb, Michael Kreuter, Hillario Nunes, Wibke Stansen, Klaus Rohr, Giichi Inoue
European Respiratory Journal 2021 58: PA3748; DOI: 10.1183/13993003.congress-2021.PA3748
Marlies S. Wijsenbeek
1Department of Respiratory Medicine, Erasmus MC, University Medical Centre, Rotterdam, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: m.wijsenbeek-lourens@erasmusmc.nl
Paolo Spagnolo
2Università degli Studi di Padova, Clinica di Malattie dell’Apparato Respiratorio, Padova, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Kolb
3McMaster University and St. Joseph’s Healthcare, Hamilton, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Kreuter
4Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Care Medicine, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hillario Nunes
5Department of Pulmonology, Hôpital Avicenne, APHP, Bobigny, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wibke Stansen
6Boehringer Ingelheim GmbH & Co. KG, Ingelheim am Rhein, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klaus Rohr
7Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giichi Inoue
8Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai City, Osaka, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

Background: The INBUILD trial enrolled patients with progressive fibrosing ILDs other than IPF. It is unclear whether, as observed in patients with IPF, patients with fibrosing ILDs who have worse scores on patient-reported outcomes assessing symptoms or health-related quality of life (HRQL) are at greater risk of ILD progression.

Aim: To assess associations between patient-reported outcomes at baseline and progression of fibrosing ILDs in the INBUILD trial.

Methods: Associations between the King's Brief ILD (K-BILD) questionnaire total score and Living with Pulmonary Fibrosis (L-PF) questionnaire symptoms dyspnoea domain score at baseline and time to ILD progression (absolute decline in FVC ≥10% predicted) or death during the INBUILD trial were assessed using Cox’s regression models.

Results: At baseline, mean (SD) K-BILD total and L-PF symptoms dyspnoea domain scores were 52.4 (10.5) (n=662) and 21.7 (18.0) (n=652), respectively, on scales of 0–100. Median exposure to trial drug was 17.4 months. In both treatment groups, baseline K-BILD total scores or L-PF symptoms dyspnoea domain scores that indicated worse HRQL were associated with a higher risk of ILD progression or death during the trial (Figure).

Conclusions: In patients with progressive fibrosing ILDs, worse scores on patient-reported outcomes are associated with a higher risk of ILD progression or death.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
  • Treatments
  • Quality of life
  • Orphan diseases

Footnotes

Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3748.

This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2021
Previous
Back to top
Vol 58 Issue suppl 65 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Do worse scores on patient-reported outcomes predict the progression of interstitial lung disease (ILD)?
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Do worse scores on patient-reported outcomes predict the progression of interstitial lung disease (ILD)?
Marlies S. Wijsenbeek, Paolo Spagnolo, Martin Kolb, Michael Kreuter, Hillario Nunes, Wibke Stansen, Klaus Rohr, Giichi Inoue
European Respiratory Journal Sep 2021, 58 (suppl 65) PA3748; DOI: 10.1183/13993003.congress-2021.PA3748

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Do worse scores on patient-reported outcomes predict the progression of interstitial lung disease (ILD)?
Marlies S. Wijsenbeek, Paolo Spagnolo, Martin Kolb, Michael Kreuter, Hillario Nunes, Wibke Stansen, Klaus Rohr, Giichi Inoue
European Respiratory Journal Sep 2021, 58 (suppl 65) PA3748; DOI: 10.1183/13993003.congress-2021.PA3748
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis
  • Evaluation of three dyspnea questionnaires in the progression of Interstitial Lung Diseases
  • IPF cluster analysis highlights diagnostic delay and cardiovascular comorbidities association with outcome
Show more Idiopathic interstitial pneumonias

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society